Ciprofloxacin (85721-33-1),Ciprofloxacin (85721-33-1) Manufacturers & Suppliers,Synthesis,MSDS

Basic information

Name:
3-Quinolinecarboxylicacid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
Superlist Name:
Ciprofloxacin
CAS No.:
85721-33-1
Molecular Structure:
Formula:
C₁₇H₁₈F N₃ O₃
Molecular Weight:
331.34
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid;1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacid;BAY-q 3939;Catex;Ciflafin;Ciprine;Cipro IV;Ciprobay 100;Ciprofloxacillin;Ciprofloxacin;Ciprofloxacine;Ciprolet;Ciprolet DS;Cipromed;Cipropol;Ciprovet;Ciproxim;Ciproxina;Cunesin;Cyclofloxacin;Euciprin;Oftacifox;Procip;Quinox XR;
Density:
1.461 g/cm³
Melting Point:
255-257 °C
Boiling Point:
581.774 °C at 760 mmHg
Flash Point:
305.646 °C
Appearance:
White powder
Hazard Symbols:
Xi
Risk Codes:
36/37/38
Safety Description:
26-36 Details

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Chemistry

IUPAC Name: 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-4-ium-1-ylquinoline-3-carboxylate
Molecular Formula: C₁₇H₁₈FN₃O₃
Molecular Weight: 331.341523 g/mol
Appearance: White Powder
Melting Point: 255-257 °C
storage temp.: Store at 0-5 °C
Merck: 13,2337
Density: 1.461 g/cm³
Flash Point: 305.6 °C
Index of Refraction: 1.655
Surface Tension: 67.4 dyne/cm
Enthalpy of Vaporization: 91.5 kJ/mol
Boiling Point: 581.8 °C at 760 mmHg
Vapour Pressure: 2.24E-14 mmHg at 25 °C
Synonyms of Ciprofloxacin (CAS NO.85721-33-1): 1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarbox ; ciloxan; ciprobid ; ciproiv ; euciprin ; ciprobay ; ciprofloxacin ; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
Categories: Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals

History

Ciprofloxacin (CAS NO.85721-33-1) was first introduced as the broad-spectrum oral fluoroquinolone in 1987 by Bayer. In 1991 the intravenous formulation was introduced. Ciprofloxacin (85721-33-1) was first patented Jan 21, 1986, in Germany, and was later approved by the U.S. Food and Drug Administration on October 22, 1987.

Uses

Ciprofloxacin (CAS NO.85721-33-1) is a third-generation quinolone antibiotics used for the treatment of respiratory tract infections, urinary tract, ENT, skin and soft tissue, gastrointestinal tract infections. It is also used as fluorinated quinolone antibacterial.

Toxicity Data With Reference

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	LDLo	oral	5714ug/kg/2D- (5.714mg/kg)	BEHAVIORAL: COMA LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" LIVER: LIVER FUNCTION TESTS IMPAIRED	Lancet. Vol. 343, Pg. 738, 1994.
man	TDLo	oral	21mg/kg/3D-I (21mg/kg)	KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED KIDNEY, URETER, AND BLADDER: PROTEINURIS KIDNEY, URETER, AND BLADDER: HEMATURIA	Annals of Pharmacotherpy. Vol. 29, Pg. 84, 1995.
man	TDLo	oral	21429ug/kg/3D (21.429mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: TOXIC PSYCHOSIS	Annals of Pharmacotherpy. Vol. 26, Pg. 930, 1992.
man	TDLo	oral	129mg/kg/6D-I (129mg/kg)	BEHAVIORAL: REGIDITY	Journal of Clinical Psychiatry. Vol. 54, Pg. 115, 1993.
man	TDLo	oral	200mg/kg (200mg/kg)	BEHAVIORAL: TREMOR GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: OTHER CHANGES	Annals of Pharmacotherpy. Vol. 28, Pg. 805, 1994.
mouse	LD50	intraperitoneal	1165mg/kg (1165mg/kg)		Ensho. Japanese Journal of Inflammation. Vol. 11, Pg. 343, 1991.
mouse	LD50	intravenous	122mg/kg (122mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Korean Journal of Toxicology. Vol. 8, Pg. 161, 1993.
mouse	LD50	oral	5gm/kg (5000mg/kg)		Journal of Medicinal Chemistry. Vol. 33, Pg. 1344, 1990.
mouse	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
rat	LD50	intravenous	207mg/kg (207mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Korean Journal of Toxicology. Vol. 8, Pg. 161, 1993.
rat	LD50	oral	> 2gm/kg (2000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
rat	LD50	subcutaneous	> 1gm/kg (1000mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 27, Pg. 297, 1992.
women	TDLo	multiple routes	40mg/kg/6D-I (40mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Acta Clinica Belgica. Vol. 49, Pg. 173, 1994.
women	TDLo	oral	10mg/kg (10mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING	Allergy. Vol. 50(Suppl,
women	TDLo	oral	40mg/kg/2D-I (40mg/kg)	BEHAVIORAL: HEADACHE BLOOD: EOSINOPHILIA	American Journal of Medicine. Vol. 87, Pg. 589, 1989.
women	TDLo	oral	135mg/kg/3D-I (135mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Archives of Internal Medicine. Vol. 153, Pg. 1258, 1993.
women	TDLo	oral	280mg/kg/2W-I (280mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: INTERSTITIAL NEPHRITIS SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"	American Journal of Kidney Diseases. Vol. 22, Pg. 598, 1993.

Safety Profile

Safety Information of Ciprofloxacin (CAS NO.85721-33-1):
Hazard Codes: Xi
Risk Statements: 36/37/38
36/37/38:Irritating to eyes, respiratory system and skin
Safety Statements: 26-36
26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
36:Wear suitable protective clothing
WGK Germany: 2
RTECS: VB1993800